Last reviewed · How we verify
Anti-hyperglycemic Agents
Anti-hyperglycemic Agents is a Anti-hyperglycemic agent (class umbrella term) Small molecule drug developed by National Heart, Lung, and Blood Institute (NHLBI). It is currently in Phase 3 development for Type 2 diabetes mellitus, Hyperglycemia management. Also known as: glimepiride (Amaryl), metformin (Glucophage), repaglinide (Gluconorm, Prandin), rosiglitazone (Avandia).
Anti-hyperglycemic agents work by reducing blood glucose levels through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption inhibition.
Anti-hyperglycemic agents are used to treat conditions such as type 2 diabetes mellitus, cardiovascular diseases, and hypertension. Examples of these agents include oral hypoglycemic agents like empagliflozin, which have been studied in combination with other substances such as vitamin D and K2 in clinical trials.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Anti-hyperglycemic Agents |
|---|---|
| Also known as | glimepiride (Amaryl), metformin (Glucophage), repaglinide (Gluconorm, Prandin), rosiglitazone (Avandia), pioglitazone (Actos) |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Drug class | Anti-hyperglycemic agent (class umbrella term) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | Phase 3 |
Mechanism of action
This is a broad drug class rather than a single agent, encompassing multiple mechanistic approaches to lower blood glucose in diabetes. Common mechanisms include stimulating pancreatic beta cells to release insulin (sulfonylureas, meglitinides), improving cellular insulin sensitivity (thiazolidinediones, metformin), inhibiting glucose reabsorption in the kidney (SGLT2 inhibitors), or slowing carbohydrate digestion (alpha-glucosidase inhibitors).
Approved indications
- Type 2 diabetes mellitus
- Hyperglycemia management
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance
- Weight gain
- Lactic acidosis (metformin-associated)
Key clinical trials
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients (NA)
- Lifestyle Intervention to Treat Diabetes in the Marshall Islands (NA)
- Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio
- Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004) (PHASE3)
- Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus (PHASE3)
- Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease (PHASE4)
- MedStar Health Type 2 Diabetes Pathway to Control (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-hyperglycemic Agents CI brief — competitive landscape report
- Anti-hyperglycemic Agents updates RSS · CI watch RSS
- National Heart, Lung, and Blood Institute (NHLBI) portfolio CI
Frequently asked questions about Anti-hyperglycemic Agents
What is Anti-hyperglycemic Agents?
How does Anti-hyperglycemic Agents work?
What is Anti-hyperglycemic Agents used for?
Who makes Anti-hyperglycemic Agents?
Is Anti-hyperglycemic Agents also known as anything else?
What drug class is Anti-hyperglycemic Agents in?
What development phase is Anti-hyperglycemic Agents in?
What are the side effects of Anti-hyperglycemic Agents?
Related
- Drug class: All Anti-hyperglycemic agent (class umbrella term) drugs
- Manufacturer: National Heart, Lung, and Blood Institute (NHLBI) — full pipeline
- Therapeutic area: All drugs in Endocrinology / Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Indication: Drugs for Hyperglycemia management
- Also known as: glimepiride (Amaryl), metformin (Glucophage), repaglinide (Gluconorm, Prandin), rosiglitazone (Avandia), pioglitazone (Actos)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing